Trial news: The AGITG currently has ten studies open to recruitment and ten studies in follow up.
The table below details the trials that are currently accruing patients.
| Recruited | Target | |
| ACTICCA-1- Gallbladder carcinoma | 3 | 50 |
| ASCOLT — Colorectal cancer | 289 | 300 |
| CONTROL NETs — NeuroEndocrine Tumour | 70 | 75 |
| INTEGRATE II – Gastro-Oesophageal | 32 | 90 |
| NABNEC — NeuroEndocrine Tumour | 21 | 70 |
| TOP GEAR — Stomach cancer | 195 | 280 |
| DYNAMIC-III | 37 | 1,000 |
| SPAR | 1 | 222 |
| LIBERATE | 4 | 100 |
Trial Results Lay Summaries (click on the links below):Recruitment figures to end May 2018.
ALaCaRT
ATTACHE
ATTAX-3
GAP
ICECREAM
INTEGRATE
TACTIC
TOP GEAR
CO.17
EORTC 62024
Advanced GIST